Deep Vein Thrombosis News and Research

RSS

Deep vein thrombosis, or DVT, is a blood clot that forms in a vein deep in the body. Most deep vein clots occur in the lower leg or thigh. If the vein swells, the condition is called thrombophlebitis. A deep vein thrombosis can break loose and cause a serious problem in the lung, called a pulmonary embolism, or a heart attack or stroke.

Discovery may help those susceptible to deep-vein thrombosis, strokes and recurrent miscarriages

Australian researchers at University of New South Wales have identified a mechanism than can cause blood clots - a discovery with implications for those susceptible to deep-vein thrombosis, strokes and recurrent miscarriages.

7 Jun 2004

BMA calls for action to safeguard the health of air passengers

The British Medical Association is calling for national and international action to safeguard the health of air passengers, in a new report published on Monday (31st May). Despite numbering two billion a year, air travellers are not protected by regulated standards of healthcare or medical advice.

31 May 2004

Anti-clotting treatment underused at many hospitals

Academic hospitals are more likely than community or Veteran’s Administration (VA) hospitals to follow national guidelines for treating patients at risk for blood clots with aspirin or warfarin.

19 May 2004

Computer prescribing systems in UK general practices are endangering patients’ lives

Computer prescribing systems in UK general practices are endangering patients’ lives by failing to pick up on some hazardous drug combinations, say researchers in this week’s British Medical Journal.

14 May 2004

Estrogen-alone hormone therapy had no effect on coronary heart disease risk

A large, multi-center heart disease prevention study, part of the Women's Health Initiative (WHI), found that estrogen-alone hormone therapy had no effect on coronary heart disease risk but increased the risk of stroke for postmenopausal women.

13 Apr 2004

Anti-blood clotting OJ from University of Liverpool

An anti-blood clotting drink has been developed by an up-and-coming biotechnology business based at the University of Liverpool’s Business Incubator, MerseyBIO. Provexis, a medical food company, is in the final stages of its large-scale trial on the new orange juice drink that has been shown to lower the chance of blood clots and thereby reduce risk of heart attack, stroke and the development of deep vein thrombosis.

22 Mar 2004